

OCT 18 2011

510(k) Summary

Introduction	According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
---------------------	--

Submitter name, address, contact	<p>Roche Diagnostics 9115 Hague Road, P.O. Box 50416 Indianapolis, IN 46250-0416 317-521-3577</p> <p>Contact Person: Michael Leuther, Ph.D. Phone: 317-521-3930 Fax: 317-521-2324 Email: michael.leuther@roche.com</p> <p>Secondary Contact: Stephanie Greeman Phone: 317-521-2458 Fax: 317-521-2324 Email: stephanie.greeman@roche.com</p> <p>Date Prepared: August 29, 2011</p>
---	---

Device Name	<p>Proprietary name: Elecsys T4 CalCheck 5 Common name: T4 CalCheck 5 Classification name: Single (specified) analyte controls (assayed and unassayed)</p>
--------------------	--

Predicate device	The Elecsys T4 CalCheck 5 is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys T3 CalCheck 5 (K111552).
-------------------------	--

Device Description	The Elecsys T4 CalCheck 5 is a lyophilized product consisting of T4 in human serum matrix. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.
---------------------------	---

Intended use	The Elecsys T4 CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys T4 reagent on the indicated Elecsys and cobas e immunoassay analyzers, for in vitro diagnostic use only.
---------------------	---

Continued on next page

510(k) Summary, Continued

Comparison Table

The table below compares Elecsys T4 CalCheck 5 with the predicate device, Elecsys T3 CalCheck 5 (K111552). The predicate shows that T4 CalCheck 5 is substantially equivalent to T3 CalCheck 5, with several key similarities. The shaded fields indicate similar characteristics between the candidate device and the predicate device.

Characteristic	Elecsys T3 CalCheck 5 (Predicate Device, K111552)	Elecsys T4 CalCheck 5 (Candidate Device)
Intended Use	The Elecsys T3 Calcheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys T3 quantitative assay reagent on the indicated Elecsys and cobas e immunoassay analyzers.	The Elecsys T4 Calcheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys T4 reagent on the indicated Elecsys and cobas e immunoassay analyzers.
Analyte	Triiodothyronine (T3)	Thyroxine (T4)
Levels	Five	Five
Assay Measuring Range	0.300 – 10.0 nmol/L	5.40 – 320 nmol/L
Check Target Values	Check 1: ≤ 0.2 nmol/L Check 2: 2.0 nmol/L Check 3: 5 nmol/L Check 4: 8 nmol/L Check 5: 10 nmol/L	Check 1: ≤ 0.78 ug/dL, ≤ 10 nmol/L Check 2: 7.77ug/dL, 100 nmol/L Check 3: 12.43ug/dL, 160 nmol/L Check 4: 19.42ug/dL, 250 nmol/L Check 5: 24.86ug/dL, 320 nmol/L
Format	Lyophilized	Lyophilized
Handling	Reconstitute Check 1, Check 2, Check 3, Check 4, and Check 5 with exactly 1.0 mL distilled or deionized water. Allow to stand closed for 15 minutes, then mix gently by inversion.	Reconstitute Check 1, Check 2, Check 3, Check 4, and Check 5 with exactly 1.0 mL distilled or deionized water. Allow to stand closed for 15 minutes, then mix gently by inversion.
Stability	<u>Unopened:</u> • Store at 2-8°C until expiration date <u>Reconstituted:</u> • 20-25°C: 4 hours	<u>Unopened:</u> • Store at 2-8°C until expiration date <u>Reconstituted:</u> • 20-25°C: 4 hours
Matrix	Human Serum matrix	Check 1: BSA/Buffer matrix Checks 2-5: Human serum
Traceability	The assayed value of each CalCheck level was standardized against reference standards by weighing T3 into an analyte free human serum matrix.	Thyroxine is traceable to the reference method ID-GC/MS using serum/plasma samples as reference material

Performance Characteristics

The Elecsys T4 CalCheck 5 was evaluated for value assignment and stability.



Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Roche Diagnostics
c/o Dr. Michael Leuther
Manager, Regulatory Affairs
9115 Hague Road, PO Box 50416
Indianapolis, IN 46250-0416

OCT 18 2011

Re: k112528
Trade Name: Elecsys T4 CalCheck 5
Regulation Number: 21 CFR §862.1660
Regulation Name: Quality control material (assayed and unassayed).
Regulatory Class: Class I, reserved
Product Codes: JJX
Dated: August 30, 2011
Received: August 31, 2011

Dear Dr. Leuther:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Courtney H. Lias, Ph.D.
Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indication for Use

510(k) Number (if known): K112528

Device Name: Elecsys T4 CalCheck 5

Indication For Use:

The Elecsys T4 CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys T4 reagent on the indicated Elecsys and cobas e immunoassay analyzers.

Prescription Use X
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use ____
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K112528